Table 1: Demographic and clinical characteristicsaccording to treatment modalities (n =124).
Covariates |
ACT (n = 93) |
NACT (n = 31) |
p-value |
Age < 50 years ≥ 50 years |
31 (33.3%) 62 (66.7%) |
14 (45.2%) 17 (54.8%) |
0.236 |
Ethnic Malay Non-Malay |
54 (58.1%) 39 (41.9%)
|
24 (77.4%) 7 (22.6%)
|
0.053 |
Stage Early stage Advanced Stage |
39 (41.9%) 54 (58.1%) |
5 (16.1%) 26 (83.9%) |
0.009 |
Molecular subtypes Luminal A TNBC Other |
36 (38.7%) 13 (14.0%) 44 (47.3%) |
6 (19.4%) 5 (16.1%) 20 (64.5%) |
0.137 |
Chemotherapy Anthracycline based Taxane based Antharacycline + taxane |
57 (61.3%) 3 (3.2%) 33 (35.5%) |
23 (74.2%) 3 (9.7%) 5 (16.1%) |
0.066 |
Schedule modification No Modification With Modification |
41 (44.1%) 52 (55.9%) |
13 (41.9%) 18 (58.1%) |
0.834 |
Status Alive Death |
78 (83.9%) 15 (16.1%) |
15 (48.4%) 16 (51.6%) |
< 0.001 |